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Riassunto
Introduzione. ESCULAPIO è un progetto multicentrico, finanziato dal Centro per la prevenzione e il controllo delle malattie, che
ha tra i suoi obiettivi quello di sviluppare strategie per implementare le conoscenze vaccinali in differenti target di popolazione.
Obiettivi. L’U.O. della Sicilia aveva il compito di identificare i determinanti associati con l’adesione vaccinale delle vaccinazioni
raccomandate presenti nel Piano nazionale vaccini.
Disegno. Sono state condotte due revisioni sistematiche di letteratura sui determinanti associati con le vaccinazioni anti-me-
ningococco e anti-pneumococco.
Risultati. Attraverso le stringhe di ricerca specifiche sono stati trovati 188 (meningococco) e 731 (pneumococco) articoli. Sele-
zionando per data di pubblicazione (dal 2000 a oggi), nazione (Europa), tipologia di articolo (articoli originali), popolazione tar-
get (no soggetti a rischio), sono stati inclusi nell’analisi 7 (meningococco) e 4 (pneumococco) lavori. Per il meningococco il prin-
cipale fattore pro-vaccinazione è un migliore status socioeconomico, mentre la distanza dai servizi vaccinali è un determinante
negativo. I determinanti associati con la vaccinazione antipneumococcica sono una maggiore età dei genitori e la raccomanda-
zione alla vaccinazione da parte dell’operatore sanitario. Viceversa, il pagamento del vaccino implica un rifiuto vaccinale.
Conclusioni. I risultati dimostrano che il pagamento della vaccinazione costituisce una barriera fondamentale e che gli sforzi
informativi/comunicativi in tema vaccinale devono essere rivolti prevalentemente alle fasce di popolazione che necessitano di un
maggiore supporto, specialmente attraverso l’attività di counselling vaccinale da parte dell’operatore sanitario di riferimento.
(Epidemiol Prev 2015; 39(4) Suppl 1: 59-64)
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Abstract
Background. ESCULAPIO is a multicenter project, funded by the Italian Centre for Disease Prevention and Control, aimed at
implementing communication strategies to improve vaccination knowledge and attitudes among different target populations.
Objective. The objective of the Sicilian research unit was, in the first phase, to identify, through systematic literature revision,
which vaccination determinants play a role in the uptake of recommended vaccines included in the Italian Vaccination Plan.
Design. A systematic literature review was carried out on studies describing the determinants underlying pneumococcal and
meningococcal vaccination uptake. The analysis was limited to papers published in English from 2000 to date.
Results. A total of 188 (meningococcal) and 731 (pneumococcal) papers were found. After selection by publication data, coun-
try (Europe), article type (original article), target population (healthy subjects), 7 (meningococcal) and 4 ( pneumococcal) man-
uscripts were finally included in the analysis. For meningococcal vaccination a better socioeconomic status is related to vacci-
nation acceptance, whereas distance from immunization service is a negative determinant. For pneumococcal vaccination the
determinants related to vaccination uptake are older parental age and a strong vaccine recommendation. Conversely, when the
vaccine needs to be paid for, a refusal is more likely
Conclusions. Our results show that payment for vaccination is a major barrier and communication about meningococcal and
pneumococcal vaccination should be targeted towards specific population groups, especially through the counseling activities
by health professionals.
(Epidemiol Prev 2015; 39(4) Suppl 1: 59-64)
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BACKGROUND
In 2012, the Italian Centre for Disease Prevention and Con-
trol (CCM) of the Ministry of Health, funded a multicenter
research project presented by researchers of six Italian regions
(Toscana: leading proponent; Liguria, Puglia, Sardegna, Sicilia,
Veneto) entitledDevelopment of health communication strategies
and interventions on preventable diseases and vaccination to in-
crease vaccine coverage in the general population. For every region,
a research unit constituted by researchers from universities or
Local Public Health authorities was identified, with specific
population targets. The project was finally renamed with the
acronym ESCULAPIO. The target for the Sicilian research
unit was the evaluation of the determinants related with vac-
cination uptake among the general population. In particular,
in a first phase of the study, the Sicilian Unit conducted sys-
tematic literature reviews (SLR) for the most important op-
tional vaccinations recommended by the Italian National Vac-
cination Plan (Human papillomavirus, influenza, measles,
mumps and rubella, meningococcal, pneumococcal).1
In this manuscript, data on studies describing the determinants
underlying pneumococcal and meningococcal vaccination up-
take among the general population are reported.
Meningococcal vaccination
Meningococcal vaccination is a relatively recent public health ac-
quisition. Despite meningococcal polysaccharide vaccines having
been available for several decades, effectiveness was not satisfactory.2
The first conjugate vaccine against Neisseria meningitidis
serogroup Cwas approved only in 1999.2 In the following years,
the introduction of the quadrivalent conjugate vaccine against
Neisseria meningitidis serogroups A, C, W135, and Y improved
the vaccination offer. Nevertheless, for many years the meningo-
coccal quadrivalent vaccine was recommended only for some
groups of the population, according to socio-occupational (e.g.,
soldiers, males who have sex withmales, travelers in high risk ar-
eas) or clinical (e.g., thalassemia, asplenia, chronic liver disease,
chronic renal failure, AIDS) characteristics.3Only in 2014, rec-
ommendations for quadrivalent meningococcal vaccination was
extended for routine infant vaccination (<2 years old).4Moreover,
in 2013 a vaccine against Neisseria meningitidis serogroup B in
infants was finally licensed.5Therefore, in the international sci-
entific literature, determinants associated withmeningococcal A,
B,W135, and Y serogroups vaccination were not analyzed, lim-
iting available data to meningococcal C vaccination.6-12
Pneumococcal vaccination
The history of pneumococcal vaccination began more than 30
years ago in the USA, where the 23-valent pneumococcal
polysaccharide vaccine (PPSV23) was licensed. Nowadays,
PPSV23 is currently recommended in people aged ≥65 years
and in high-risk adults aged 19-64 years.13However, PPSV23
has limited effectiveness against invasive pneumococcal disease,
especially among immunocompromised adults, and PPSV23
protection is short-lived, with a rapid waning of antibody
concentrations and with a lack of memory B-cell production
following immunization.14-16
Since 2000, the offer of pneumococcal vaccine has been enriched
by a conjugate 7-valent vaccine (PCV7) for all children aged 2-23
months.17 In 2010, PCV7 vaccinewas replaced by a 13-valent vac-
cine (PCV13) with six additional serotypes.13-18 Both conjugate
vaccinations demonstrated good efficacy and effectiveness in in-
vasive pneumococcal disease (IPD) prevention.19-20
On August 2014, the Advisory Committee on Immunization
Practices (ACIP) recommended routine use of PCV13 even
among adults aged ≥65 years, extending the vaccine indication
to community-acquired pneumonia.13
MATERIAL AND METHODS
AnSLRwas carried out on determinants associatedwithmeningo-
coccal and pneumococcal vaccination compliance, considering key
terms used in combination and referred to vaccine/immunization,
uptake/coverage, determinant/factor, and Neisseria meningi-
tidis/meningococcal/meningococcus or Streptococcus pneumo-
niae/pneumococcus/pneumococcal, withmedical subject headings
(MeSH) and MeSH major topics included in the syntax. The
PubMed/MEDLINE, SCOPUS, EMBASE, and ISIWeb of Sci-
ence online databases were considered, as well as the grey litera-
ture, and a manual search was performed based on the references
of the articles retrieved. Original articles published from January
2000 to December 2014 were collected (figure 1).
Qualitative and quantitative studies describing the determinants
underlyingmeningococcal or pneumococcal vaccination uptake
among parents of children or adolescents/adults were included in
the review. Exclusion criteria applied during title and abstract
screening were: articles published in a language different from
English, Italian, or French, studies conducted in non-European
countries, studies reporting vaccination information on non-
healthy populations, studies other than original articles (e.g., re-
view) (figure 1). Other exclusion criteria were applied during full
text analysis: assessing only vaccination coverage; reporting up-
take determinants not in first person or not by parents; not re-
porting direct linking with uptake (e.g., linking with adverse pub-
licity or with information-seeking) (figure 1).
Variable extraction was conducted on the basis of potential classes
of determinants identified in previous SLRs, that included among
others: knowledge, beliefs, and perceptions (both on vaccines and
diseases); attitudes/behaviours; demographics (such as ethnicity,
mother’s age, child’s age, gender, geographic location); socioeco-
nomic status (SES) (including education level, employment,
family income, number of children in the household).21
The literature search and systematic review were conducted by
two independent investigators. In case of any incongruity, the
two investigators came to an agreement after further analysis
and discussion.
RESULTS
Meningococcal vaccination
As shown in figure 1, through the standardized database search-
ing, 144 records were identified. After duplicates were re-
moved, 135 records were screened and 125 records were ex-
cluded on the basis of title and abstract screening (based on
language, study setting, methodology, or target population).
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Finally, among 11 articles assessed for eligibility, 4 were ex-
cluded on basis of exclusion criteria and 7 were analyzed in the
qualitative synthesis.
Manuscripts included in the meningococcal vaccination SLR are
summarized in table 1.
In particular, the first European experience analyzing vaccine
status and determinants of British undergraduates in South
Wales (mean age in years 18.9, 51% females), showed that the
supply of meningococcal C vaccination through school-based
campaigns (93% vaccinated vs 19% vaccinated without an ac-
tive vaccination offer) was the most important determinant for
vaccination acceptance.6
A study conducted in 2005 among 1,763 Dutch parents of
children aged 6 to 14 years old demonstrated that ethnicity, re-
ligion (not practicing), and a higher parent education level were
related with vaccination acceptance.7
Vaccination coverage (VC) reported in the study was 84%. Con-
sidering the diversity of theDutch population, analysis of the dif-
ferent ethnicities showed there was better information, risk aware-
ness, and critical attitudes towards meningococcal vaccination
among Dutch parents compared to parents of different ethnic-
ity (e.g., Turkish, Moroccan, Surinamese).7
Perceptions, attitudes, and behaviour regarding meningococcal
vaccination were also analyzed in the Netherlands among the
same group of parents.9 Specifically, a higher perceived vulnera-
bility of their own child contracting meningococcal disease and
a perceived control of vaccination in preventing meningococcal
C infection were strongly related with vaccination acceptance.9
In 2005, a retrospective study conducted in Belgium (EPI-sur-
vey), reported coverage and predictive factors associated with
childhood vaccination compliance. In particular, for meningo-
coccal vaccination (VC=94%), using the paediatrician as a ref-
erent for vaccination counselling in the multivariate analysis,
a better vaccination attitude was shown to be related with
“well-baby clinic” or “daycare” vaccination counseling (OR 1.9;
95%CI 1.2-2.8 ).8 Conversely, a family physician vaccination
counseling represents a barrier for meningococcal vaccination
(OR 0.4; 95%CI 0.2- 0.8).8
Results of the EPI-survey study among parents of 14- and 7-
year-old Belgian children were also reported.10-11 In particular,
among 14-year-old children, the determinants associated with
vaccination uptake were mother’s education (secondary school
or higher: OR 1.7; 95%CI 1.0-2.9) and employment (part-time
work: OR 1.9; 95%CI 1.4-2.7), whereas the determinants as-
sociated with vaccination refusal were the adolescent’s school ca-
reer (repeated 1 year: OR 0.6; 95%CI 0.4-0.8; special educa-
tion: OR 0.4; 95%CI 0.2-0.7), mother’s ethnicity (non
European: OR 0.4; 95%CI 0.3-0.7), and father’s employment
(part-time work: OR 0.2; 95%CI 0.0-0.8).10
Among parents of 7-year-old children, vaccination uptake was
strongly related with higher family income (>€3,000/month:
OR 2.92; 95%CI 1.39-6.09).11
Figure 1. Flow SLR diagram of the determinants of pneumococcal (A) and meningoccocal (B) vaccination.
Figura 1. Diagramma di flusso delle RSL relative ai determinanti delle vaccinazioni antimeningococco (A) e antipneumococco (B).
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Finally, a cross-sectional survey conducted in Poland among
parents of 0-5 years olds children highlighted lower meningo-
coccal VC than the Netherlands and Belgium.12
Vaccination compliance was related with older parental age
(>25 years: OR 2.60; 95%CI 1.03-6.83), higher socio-eco-
nomic status of the family (OR 3.46; 95%CI 1.95-8.48), num-
ber of children (one: OR 3.64; 95%CI 1.96-7.14), and area of
family physician practice (town: OR 3.94; 95%CI 1.95-8.48).12
High cost of the vaccine was associated with vaccination refusal
(OR 0.18; 95%CI 0.09-0.36).12
Pneumococcal vaccination
For pneumococcal vaccination, 731 records were identified
through the database search (figure 1). After duplicates were re-
moved, 683 records were screened and 656 records were ex-
cluded on the basis of title and abstract screening (based on lan-
guage, study setting, methodology or target population). Finally,
among 27 articles assessed for eligibility, 23 were excluded on
the basis of the exclusion criteria and 4 were analyzed in the
qualitative synthesis. Manuscripts included in the pneumo-
coccal vaccination SLR are summarized in table 2.12,22-24
The first article analyzed was a survey conducted in 2002 on
a sample of adults ≥65 years of age conducted in 11 Italian re-
gions.22 Vaccination coverage reported for PPSV23 was only
5%. Factors associated with vaccination uptake were a strong
recommendation by the family general practitioner (GP), free-
of -charge vaccination, and perception of the danger of pneu-
mococcal disease.22
In 2009, a cross-sectional study was conducted among parents
of 0-5 year old Polish children to measure coverage and de-
terminants of self-paid vaccinations.12 Factors associated with
PCV7 pneumococcal vaccination uptake were the same as
Manuscript Geographical setting/ Adolescents (own vaccination) Parents (vaccination on their child) Type of determinant
(1st author, journal, target population facilitator barrier facilitator barrier
publication date)
Thirlaway K6 UK ■ UK residence Irish residence ■ demographic factors
Commun Dis Public Health undergraduates ■ living in student (residence)
2003 (18-21 years old) accommodation ■ socio-economic factors
■ school-based (accommodation type)
vaccination ■ vaccination strategies
program
Timmermans D et al.7 Netherlands ■ ethnicity (Dutch); ■ demographic factors
Vaccine parents of children ■ religion (ethnicity, religion)
2005 6-14 years old (not practicing) ■ parents’ education
■ higher parental level
education level
Theeten H et al.8 Belgium main vaccinating main vaccinating type of health care
Vaccine parents of children physician: physician: workers recommending
2007 18-24 months well-baby clinic family physician vaccination
or daycare (referent:
(referent: pediatrician) pediatrician)
Timmermans D et al.9 Netherlands ■ perceived vulnerability psychosocial factors
BMC Public Health parents of children of their own child (perceptions, attitudes,
2008 6-14 years old ■ perceived control and behaviours)
in preventing
meningococcal
infection
Vandermeulen C et al.10 Belgium school career ■ higher mother’s ■race of the mother ■ demographic factors
Pediatrics parents of adolescents of adolescent education (non European) (race)
2008 14 years old (repeated 1 year, ■ mother’s ■father’s ■ education level
special education) employment employment (parents)
(part-time work) (part-time work) ■ employment type
(parents)
■ education-related
factors (adolescent)
Theeten H et al.11 Belgium higher socioeconomic socioeconomic factors
Acta Paediatr parents of children status (family income) (family income)
2009 7 years old
Ganczak M et al.12 Poland ■ age ≥25 years old ■number of children ■ demographic factors
Vaccine parents of children ■ number of children in the family (parents’ age,
2013 0-5 years old in the family (one) (more than one) number of children)
■ higher socioeconomic ■high cost ■ socioeconomic factors
status (family income) of the vaccine (family income)
■ area of family ■ family physician
physician practice related factors
(town) (area of practice)
■ cost of the vaccine
Table 1. Determinants for meningococcal vaccination reported in the manuscripts included in the systematic literature review.
Tabella 1. Determinanti associati con la vaccinazione antimeningococcica inclusi negli articoli della revisione sistematica di letteratura.
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those reported above for meningococcal vaccination.12 Amul-
ticenter survey carried out in 13 Western European countries
investigated attitudes to vaccination in people aged >50 years.23
As reported in table 2, the principal determinants for pneumo-
coccal vaccination uptake were perception of vaccination effi-
cacy and effectiveness and a strong recommendation from the
GP. Similarly, factors associated with vaccine refusal were: lack
of physician recommendation or vaccine awareness, and not be-
ing concerned about pneumococcal infections.
Finally, the results of two cross-sectional studies performed in
2012 in two Belgian regions among parents of 18-24months-old
children were reported.24
The predictor most often and most strongly associated with
PCV7 vaccination was Mother and Child clinic attendance
(Wallonia region: OR 2.8; 95%CI 1.5-5.1; Brussels-Capital re-
gion: OR 4.8; 95%CI 2.4-9.4).24 InWallonia, having only one
child was related with higher vaccination uptake (OR 2.8;
95%CI 1.3-6.0). Higher vaccination rates were also observed
in Brussels-Capital Region among children who attended a
daycare centre (OR 2.1; 95%CI 1.0-4.5).24
DISCUSSION
Meningococcal vaccination
Meningococcal C vaccination is a fundamental measure to pre-
vent invasive meningococcal disease (IMD) among children
and adolescents.25 According to our revision, in countries with
an active universal meningococcal vaccination program like the
Netherlands and Belgium, uptake among parents of European
children is strongly related with higher education level and so-
cioeconomic status of the parents.7,10-12,26
Probably, in these cases, parents have higher awareness regarding
meningococcal vaccination.9 In particular, parents in Belgium can
choose to have their child immunized in Mother and Child
health or well-baby clinics, which are public organizations, or by
a practitioner. Administration is free of charge when performed
at the clinics, while a fee must be paid if the vaccine is adminis-
tered by a GP or a pediatrician.26 For these reasons, appropriate
counseling about vaccination strategies represents an essential de-
terminant for parents of 18-24month old children in Belgium.8
Conversely, in Poland pneumococcal vaccine is not included in
the national immunization program.26
Nevertheless, in addition to free-of-charge vaccines listed in the
mandatory immunization schedule, self-paid vaccinations are
also recommended for Polish children (pneumococcal, meningo-
coccal, rotavirus, etc.).26 Indeed, in this context, determinants
of vaccination uptake/refusal were mainly socioeconomic (fam-
ily income, cost of the vaccine).26
Moreover, older parent age and a small number of children in
the family, predictors that are already known in the literature and
may be associated with higher socioeconomic status, were related
with higher vaccination coverage.26,27
Among adolescents, a British study demonstrated the benefit of
a school-based vaccination program.7 In particular, UK students
demonstrated better meningococcal vaccination coverage and at-
titudes compared to Irish student (no school-based vaccination
strategy was implemented in Ireland).7
Pneumococcal vaccination
The value of pneumococcal conjugate vaccination in IPD pre-
vention is recognized worldwide.19,20Nonetheless, in some Eu-
Manuscript Geographical Adolescents (own vaccination) Parents (vaccination on their child) Type of determinant
(1st author, journal, setting; target facilitator barrier facilitator barrier
publication date) population
Sammarco S et al.22 Italy ■ strong vaccine ■ psychosocial factors
Annali di Igiene people aged ≥65 recommendation (perceptions, attitudes,
2004 years old ■ free vaccination and behaviours)
■ perceived ■ vaccination strategies
dangerous
disease
Ganczak M et al.12 Poland ■ age ≥25 years ■ high cost ■ demographic factors
Vaccine parents of children ■ number of children of the vaccine (parents’ age, family
2013 0-5 years old in the family (one) composition)
■ higher ■ socioeconomic factors
socioeconomic (family income)
status ■ family physician
(family income) related factors
(area of practice)
■ cost of the vaccine
Lode H et al.23 13Western European ■ perception of ■ lack of physician ■ psychosocial factors
Advances in Therapy countries vaccine efficacy recommendations (perceptions, attitudes,
2013 adults aged >50 years and effectiveness ■ vaccine awareness and behaviours)
■ health care ■ not being concerned
worker about pneumococcal
recommendation infections
Robert E et al.24 Belgium ■ attending Mother ■ vaccination strategies
BioMed Research Intern parents of children & Child clinics ■ demographic factors
2014 aged 18-24 months or a daycare (number of children)
■ number of children in the family (one)
Table 2. Determinants for pneumococcal vaccination reported in the manuscripts included in the systematic literature review.
Tabella 2. Determinanti associati con la vaccinazione antipneumococcica inclusi negli articoli della revisione sistematica di letteratura.
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ropean countries this is a recommended self-paid vaccination for
children.26 Therefore, in Poland the principal determinants re-
lated with vaccination uptake were socioeconomic (family in-
come, cost of vaccination, etc.), similarly to those observed for
meningococcal vaccination in the same country.12 Likewise in
Belgium, where pneumococcal vaccination was fully offered only
inmother and child clinics or in daycare centres, vaccination cov-
erage was higher precisely in these contexts.24,26Moreover, like
in Poland, having only one child was a socioeconomic determi-
nant associated with vaccination adherence.12,24
Conversely, among healthy European adults PPSV23 vacci-
nation uptake was related with a strong recommendation by
their own general practitioner.22,23 Furthermore, the percep-
tion of pneumococcal disease danger and the perception of vac-
cination efficacy and effectiveness were factors strongly linked
with adequate counseling by health care professionals.22,23
CONCLUSIONS
Our results show that communication and information about
meningococcal and pneumococcal vaccination for newborns
and children should be targeted towards specific groups of par-
ents (low income or cultural level, younger age, different ethnic-
ity). Moreover, it is essential to organize universal free-of-charge
vaccination strategies. For healthy adults, conversely, the health
professional’s counseling activities on PPSV23 and in future on
PCV13 vaccinations should be targeted on pneumococcal disease
danger and pneumococcal vaccination efficacy and effectiveness.
A strong recommendation for pneumococcal vaccination from
general practitioners and a free-of-charge vaccination plan
would also be important strategies.
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